Patents by Inventor Hiroyuki Ebinuma
Hiroyuki Ebinuma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11702688Abstract: An object of the present invention is to provide a novel method for designing a primer ensuring reactivity and discriminatory power in a method for detecting a single base substitution based on an ASP-PCR method and to provide a method for easily detecting multiple point mutations within overlapping amplicons, particularly, two adjacent single base substitutions. The single base substitutions can easily be detected by using a mutant primer in which the base of the third nucleotide from the 3? end corresponds to the base of a mutant nucleotide of a single base substitution contained in a nucleic acid sample, in which the base of the second nucleotide from the 3? end is not complementary to the base of the corresponding nucleotide of the nucleic acid, and in which the bases of the other nucleotides are complementary to the bases of the corresponding nucleotides of the nucleic acid.Type: GrantFiled: March 29, 2017Date of Patent: July 18, 2023Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki Ebinuma, Katsura Uchida, Yuriko Tsukamoto
-
Publication number: 20230090926Abstract: It is an object of the present disclosure to provide a method for reducing the influence of baseline disturbances in a method for detecting a target nucleic acid in dry blood filter paper by real-time PCR using a fluorescent dye, with a simple method. The present disclosure provides a method for detecting a target nucleic acid in dry blood filter paper by real-time PCR, the method including: (1) amplifying the target nucleic acid in the dry blood filter paper by applying thermal cycles to a sample solution containing a dry blood filter paper punch piece and a PCR reagent, wherein the PCR reagent includes a fluorescently labeled probe; (2) optically detecting the fluorescence intensity of the sample solution for each of the thermal cycles; and (3) performing quantitative analysis of the target nucleic acid using data after a predetermined number of cycles of the optically detected data.Type: ApplicationFiled: February 19, 2021Publication date: March 23, 2023Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki EBINUMA, Ikumi SUZUKI
-
Patent number: 11566074Abstract: Provided are a method of efficiently producing an sIL-2R antigen in an amount necessary for antibody generation, and a method of producing an anti-sIL-2R antibody using the antigen. Specifically, provided are a method of producing soluble interleukin-2 receptor, including culturing SCC-3 cells and recovering soluble interleukin-2 receptor from a culture of the cells, and a method of producing an anti-soluble interleukin-2 receptor antibody, including immunizing an animal with sIL-2R produced by the method.Type: GrantFiled: September 29, 2016Date of Patent: January 31, 2023Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki Ebinuma, Kengo Fujimura
-
Publication number: 20220316000Abstract: An object of the invention is to provide an optical detection method and a quantification method of a product obtained by amplifying a target nucleic acid contained in a paper piece of a blood spot in a filter paper obtained by blotting blood on a filter paper and then drying the blood using nucleic acid amplification reaction by real-time PCR and to further provide a kit used for the methods. The invention provides a method and a kit which can optically detect and quantify a target nucleic acid from a dried blood spot in a filter paper by real-time PCR without any complicated pretreatment, by adjusting the size of the punched piece of the dried blood spot in a filter paper or the whole blood amount contained in the punched piece, the amount of the PCR reaction reagent, or performing the PCR reaction in a PCR reaction tube closed with a cap.Type: ApplicationFiled: September 11, 2020Publication date: October 6, 2022Applicants: SEKISUI MEDICAL CO., LTD., NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENTInventors: Hiroyuki EBINUMA, Hiroaki INOUE, Toru UCHIYAMA
-
Publication number: 20220267852Abstract: An object of the invention is to provide a primer for detecting and quantifying homozygous deletion of the SMN1 gene, the deletion of which causes SMA, using a dried blood spot in a filter paper and a method related to specific detection/quantification of the SMN1 gene using the primer.Type: ApplicationFiled: July 22, 2020Publication date: August 25, 2022Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki EBINUMA, Ikumi SUZUKI
-
Patent number: 11155805Abstract: An object of the present invention is to provide an efficient nucleic acid recovery method capable of concentrating a nucleic acid from a sample containing a nucleic acid such that the nucleic acid is usable in gene amplification reaction. To solve the problem, the present inventors have found that by targeting a protein to which a nucleic acid is bound (hereinafter also referred to as a nucleoprotein or a protein-nucleic acid complex) rather than targeting the nucleic acid itself, or specifically, by causing a specific antibody against the protein to act, the nucleic acid can be captured simultaneously with the protein, and thereby completing the present invention. Furthermore, the present inventors have found that if animal cells, bacteria, viruses, etc.Type: GrantFiled: March 27, 2018Date of Patent: October 26, 2021Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki Ebinuma, Katsura Uchida
-
Publication number: 20210079456Abstract: An object of the present invention is to provide a method for highly sensitively detecting, and a method for quantifying, a mutant gene (mutant allele) contained at a low frequency in a nucleic acid sample containing a wild-type allele. In one-reaction system in which a first-primers set designed to flank a mutation site of a gene of interest is mixed with a second-primers set including an ASP corresponding to the mutation, an amplification product can be obtained from a low-frequency mutant gene, and quantitativeness can be ensured, by including a competitive nucleic acid suppressing an amplification reaction from a wild-type allele of the gene, selecting a certain primer concentration condition, and controlling the cycle numbers of PCR reactions using the first and second-primers sets.Type: ApplicationFiled: July 25, 2018Publication date: March 18, 2021Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki EBINUMA, Yuriko TSUKAMOTO
-
Patent number: 10626452Abstract: An object of the present invention is to provide a method for accurately and quantitatively discriminating and detecting a wide variety of gene mutations, or particularly, single base substitutions or point mutations. In an ASP for analyzing gene mutations, or particularly, single base substitutions or point mutations, when a non-nucleotide component is added to the 5? end of at least one of the ASP and a primer paired therewith before amplification by PCR and amplification products thereof are separated by ion-exchange chromatography, even the amplification products having the same length can be separated and detected.Type: GrantFiled: September 29, 2017Date of Patent: April 21, 2020Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki Ebinuma, Katsura Uchida, Yuriko Tsukamoto
-
Publication number: 20190376057Abstract: An object of the present invention is to provide an efficient nucleic acid recovery method capable of concentrating a nucleic acid from a sample containing a nucleic acid such that the nucleic acid is usable in gene amplification reaction. To solve the problem, the present inventors have found that by targeting a protein to which a nucleic acid is bound (hereinafter also referred to as a nucleoprotein or a protein-nucleic acid complex) rather than targeting the nucleic acid itself, or specifically, by causing a specific antibody against the protein to act, the nucleic acid can be captured simultaneously with the protein, and thereby completing the present invention. Furthermore, the present inventors have found that if animal cells, bacteria, viruses, etc.Type: ApplicationFiled: March 27, 2018Publication date: December 12, 2019Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki EBINUMA, Katsura UCHIDA
-
Publication number: 20190203284Abstract: An object of the present invention is to provide a method for accurately and quantitatively discriminating and detecting a wide variety of gene mutations, or particularly, single base substitutions or point mutations. In an ASP for analyzing gene mutations, or particularly, single base substitutions or point mutations, when a non-nucleotide component is added to the 5? end of at least one of the ASP and a primer paired therewith before amplification by PCR and amplification products thereof are separated by ion-exchange chromatography, even the amplification products having the same length can be separated and detected.Type: ApplicationFiled: September 29, 2017Publication date: July 4, 2019Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki EBINUMA, Katsura UCHIDA, Yuriko TSUKAMOTO
-
Publication number: 20190032123Abstract: An object of the present invention is to provide a novel method for designing a primer ensuring reactivity and discriminatory power in a method for detecting a single base substitution based on an ASP-PCR method and to provide a method for easily detecting multiple point mutations within overlapping amplicons, particularly, two adjacent single base substitutions. The single base substitutions can easily be detected by using a mutant primer in which the base of the third nucleotide from the 3? end corresponds to the base of a mutant nucleotide of a single base substitution contained in a nucleic acid sample, in which the base of the second nucleotide from the 3? end is not complementary to the base of the corresponding nucleotide of the nucleic acid, and in which the bases of the other nucleotides are complementary to the bases of the corresponding nucleotides of the nucleic acid.Type: ApplicationFiled: March 29, 2017Publication date: January 31, 2019Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki EBINUMA, Katsura UCHIDA, Yuriko TSUKAMOTO
-
Publication number: 20180273625Abstract: Provided are a method of efficiently producing an sIL-2R antigen in an amount necessary for antibody generation, and a method of producing an anti-sIL-2R antibody using the antigen. Specifically, provided are a method of producing soluble interleukin-2 receptor, including culturing SCC-3 cells and recovering soluble interleukin-2 receptor from a culture of the cells, and a method of producing an anti-soluble interleukin-2 receptor antibody, including immunizing an animal with sIL-2R produced by the method.Type: ApplicationFiled: September 29, 2016Publication date: September 27, 2018Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki EBINUMA, Kengo FUJIMURA
-
Patent number: 9969802Abstract: Provided is a detection method for a malignant tumor cell, including measuring a protein marker expressed on a malignant tumor cell surface. The detection method for a malignant tumor cell includes measuring LR11 on a cell surface in a sample to be tested.Type: GrantFiled: July 15, 2011Date of Patent: May 15, 2018Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki Ebinuma, Kohei Takubo, Isamu Fukamachi, Saishu Yoshida, Hideaki Bujo, Chiaki Nakaseko, Yasushi Saito
-
Patent number: 9541550Abstract: To provide a method for assaying soluble LR11 in a biological sample, which method realizes a simple and accurate assay of soluble LR11 present in the sample by immunological means without requiring isolation of soluble LR11 from the biological sample (e.g., a serum sample). The method of the invention for immunologically assaying soluble LR11 present in a biological sample, characterized in that the method includes treating the sample with at least one surfactant selected from among one or more sulfobetaine amphoteric surfactants and one or more amidosulfobetaine amphoteric surfactants.Type: GrantFiled: May 9, 2012Date of Patent: January 10, 2017Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Kohei Takubo, Hiroyuki Ebinuma, Isamu Fukamachi, Hideaki Bujo, Yasushi Saito
-
Patent number: 9442123Abstract: Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin.Type: GrantFiled: March 16, 2015Date of Patent: September 13, 2016Assignee: SEKISUI MEDICAL CO., LTD.Inventor: Hiroyuki Ebinuma
-
Patent number: 9261443Abstract: Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid.Type: GrantFiled: May 8, 2013Date of Patent: February 16, 2016Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Isamu Fukamachi, Hideaki Bujo, Yasushi Saito
-
Publication number: 20160018419Abstract: Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin.Type: ApplicationFiled: March 16, 2015Publication date: January 21, 2016Applicant: SEKISUI MEDICAL CO., LTD.Inventor: Hiroyuki EBINUMA
-
Patent number: 9097714Abstract: To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence. The method for determining the presence of a malignant tumor or the severity thereof, method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or method for estimating the risk of recurrence of the malignant tumor or the presence or absence of the recurrence is characterized by including 1) a step of measuring the concentration and/or quantity of soluble LR11 in a sample originating from a subject and 2) a step of comparing the value measured above with a measurement value of soluble LR11 obtained from a healthy subject group.Type: GrantFiled: December 15, 2010Date of Patent: August 4, 2015Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki Ebinuma, Kohei Takubo, Masanao Matsuo, Isamu Fukamachi, Hideaki Bujo, Chiaki Nakaseko, Yasushi Saito
-
Publication number: 20140080158Abstract: To provide a method for assaying soluble LR11 in a biological sample, which method realizes a simple and accurate assay of soluble LR11 present in the sample by immunological means without requiring isolation of soluble LR11 from the biological sample (e.g., a serum sample). The method of the invention for immunologically assaying soluble LR11 present in a biological sample, characterized in that the method includes treating the sample with at least one surfactant selected from among one or more sulfobetaine amphoteric surfactants and one or more amidosulfobetaine amphoteric surfactants.Type: ApplicationFiled: May 9, 2012Publication date: March 20, 2014Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Kohei Takubo, Hiroyuki Ebinuma, Isamu Fukamachi, Hideaki Bujo, Yasushi Saito
-
Publication number: 20140038213Abstract: Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin.Type: ApplicationFiled: October 17, 2013Publication date: February 6, 2014Applicant: SEKISUI MEDICAL CO., LTD.Inventor: Hiroyuki Ebinuma